Literature DB >> 10991993

Effect of phenylalanine and its metabolites on the proliferation and viability of neuronal and astroglial cells: possible relevance in maternal phenylketonuria.

J Oberdoerster1, M Guizzetti, L G Costa.   

Abstract

Phenylketonuria is a genetic defect that, without strict dietary control, results in the accumulation of phenylalanine (Phe) in body fluids. If a low-Phe diet is not maintained during pregnancy, the offspring of phenylketonuric women are born with mental retardation and microcephaly. Primary cultures of rat cerebellar granule cells, rat cortical astrocytes, human fetal astrocytes, and human neuroblastoma (SY5Y) cells and human astrocytoma (1321N1) cells were used to test the hypothesis that the microencephaly may be a result of neuronal cell death and reduced astrocyte proliferation. Exposure to Phe or to six Phe metabolites [phenylacetic acid (PAA), phenyllactic acid, hydroxyphenylacetic acid, phenylpyruvic acid, phenylethylamine (PEA), and mandelic acid] did not result in astroglial or neuronal cell cytotoxicity. Treatment of 1321N1 cells, human fetal astrocytes, or rat astrocytes with 5 mM Phe for 24 h decreased DNA synthesis 19 +/- 4, 30 +/- 4, and 60 +/- 6%, respectively. This effect was concentration dependent, and flow cytometry revealed that Phe treatment resulted in the accumulation of cells in the G(0)/G(1) phase of the cell cycle. In addition, in 1321N1 cells, exposure to 5 mM PAA, and in rat astrocytes, exposure to 0.5 mM PEA inhibited cell proliferation 42 +/- 4 and 55 +/- 4%, respectively. These metabolites also resulted in the accumulation of cells in the G(0)/G(1) phase of the cell cycle. In human fetal astrocytes, 0.5 mM PEA and 0.5 mM PAA resulted in a 41 +/- 12 and 52 +/- 11% reduction proliferation, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10991993

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression.

Authors:  J Jankowski; M van der Giet; V Jankowski; S Schmidt; M Hemeier; B Mahn; G Giebing; M Tolle; H Luftmann; H Schluter; W Zidek; M Tepel
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  Metabolomics analysis reveals perturbations of cerebrocortical metabolic pathways in the Pahenu2 mouse model of phenylketonuria.

Authors:  Li-Hua Lu; Zheng-Xiang Xia; Jia-Lin Guo; Ling-Ling Xiao; Yong-Jun Zhang
Journal:  CNS Neurosci Ther       Date:  2019-08-31       Impact factor: 5.243

3.  L-carnitine protects DNA oxidative damage induced by phenylalanine and its keto acid derivatives in neural cells: a possible pathomechanism and adjuvant therapy for brain injury in phenylketonuria.

Authors:  Jéssica Lamberty Faverzani; Aline Steinmetz; Marion Deon; Desirèe Padilha Marchetti; Gilian Guerreiro; Angela Sitta; Daniella de Moura Coelho; Franciele Fatima Lopes; Leopoldo Vinicius Martins Nascimento; Luiza Steffens; Jeferson Gustavo Henn; Matheus Bernardes Ferro; Verônica Bidinotto Brito; Moacir Wajner; Dinara Jaqueline Moura; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2021-07-03       Impact factor: 3.584

4.  The lactic acid bacteria metabolite phenyllactic acid inhibits both radial growth and sporulation of filamentous fungi.

Authors:  Åsa Svanström; Silvio Boveri; Emma Boström; Petter Melin
Journal:  BMC Res Notes       Date:  2013-11-14

5.  Antifungal activity of phenyllactic acid against molds isolated from bakery products.

Authors:  Paola Lavermicocca; Francesca Valerio; Angelo Visconti
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.